Search results for " Lupus Erythematosus"

showing 10 items of 77 documents

Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of…

2021

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that can be used to improve our understanding of the disease and to make a precise differential diagnosis. SPTCL, LEP, and overlapping cases were analyzed using a customized NanoString platform including 208 genes related to T-cell differentiation, stromal signatures, oncogenes, and tumor suppressor genes. Gene expression unsupervised analysis of the samples differentiated SPTCL f…

Cancer ResearchPathologymedicine.medical_specialtyPanniculitiseducationBiologyLymphoma T-CellCutaneous lymphomaDiagnosis Differential03 medical and health sciences0302 clinical medicineSubcutaneous Panniculitis-Like T-Cell LymphomaPanniculitis Lupus ErythematosusmedicineHumansT-cell lymphomahealth care economics and organizationsLupus erythematosusHematologymedicine.diseaseImmunohistochemistryLymphomaGene expression profilingOncology030220 oncology & carcinogenesisDifferential diagnosishormones hormone substitutes and hormone antagonistsLupus erythematosus panniculitis030215 immunologyLeukemia & Lymphoma
researchProduct

The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease.

2013

Recently oxacyclododecindione (Oxa), a macrocyclic lactone isolated from the imperfect fungus Exserohilum rostratum, has been described as a potent transcription inhibitor of inducible proinflammatory and profibrotic genes in cell culture models. As kidney disease in systemic lupus erythematosus is characterized by aberrant expression of inflammatory mediators and infiltration of immune cells, we investigated the effect of Oxa in MRL-Fas(lpr) mice, a model of systemic lupus erythematosus. These mice develop a spontaneous T-cell and macrophage-dependent autoimmune disease including severe glomerulonephritis that shares features with human lupus. Comparable to the results of in vitro models, …

ChemokineMice Inbred MRL lprMacrocyclic CompoundsAnti-Inflammatory AgentsProtein Array AnalysisGene ExpressionInflammationChemokine CXCL9Proinflammatory cytokineInterferon-gammaMiceImmune systemmedicineAnimalsCalgranulin ARNA MessengerChemokine CCL4Chemokine CCL5Chemokine CCL2Autoimmune diseaseSystemic lupus erythematosusbiologyInterleukin-6Tumor Necrosis Factor-alphaGlomerulonephritismedicine.diseaseLupus NephritisChemokine CXCL12Disease Models AnimalNephrologyImmunologybiology.proteinCytokinesFemaleOsteopontinmedicine.symptomKidney diseaseKidney international
researchProduct

PS7:145 Il-34, not csf-1, similarly mediates rheumatoid and lupus arthritis in patients

2018

While Myeloid cells are abundant in lupus arthritis (LA) and rheumatoid arthritis (RA), based on clinical presentation LA and RA are considered distinct diseases. Although inflammatory arthritis is common in patients with lupus, the pivotal mechanisms leading to joint damage have not been investigated. We tested the hypothesis that IL-34, but not CSF-1, is a predictive biomarker that is integral in perpetuating synovial destructive inflammation in both LA and RA. We report the novel findings that: using longitudinally tracked patients, IL–34, not CSF–1, is a clinical predictive biomarker for both LA and RA; and IL–34 is more robustly expressed in the synovial tissue, cells and fluid compare…

ChemokineSystemic lupus erythematosusbiologybusiness.industryInflammatory arthritisArthritisInflammationmedicine.diseaseSynovial CellRheumatoid arthritisImmunologymedicinebiology.proteinBiomarker (medicine)medicine.symptombusinessPoster session 7: New drugs and trageted therapy
researchProduct

Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis.

2010

Parvovirus B19 is a widespread virus with diverse clinical presentations. The viral nonstructural protein, NS1, binds to and cleaves the viral genome, and induces apoptosis when transfected into nonpermissive cells, such as hepatocytes. We hypothesized that the cytotoxicity of NS1 in such cells results from chromosomal DNA damage caused by the DNA-nicking and DNA-attaching activities of NS1. Upon testing this hypothesis, we found that NS1 covalently binds to cellular DNA and is modified by PARP, an enzyme involved in repairing single-stranded DNA nicks. We furthermore discovered that the DNA nick repair pathway initiated by poly(ADPribose)polymerase and the DNA repair pathways initiated by …

DNA RepairDNA damageViral nonstructural proteinDNA repairPoly ADP ribose polymerasevirusesBlotting WesternParvovirus B19Viral Nonstructural ProteinsCell Linechemistry.chemical_compoundsystemic lupus erythematosusParvovirus B19 HumanHumansImmunoprecipitationPolymerasebiologyfulminant liver failureDNA damage and repairapoptosisvirus diseasesGeneral MedicineTransfectionMolecular biologyProliferating cell nuclear antigenchemistrybiology.proteinDNAautoantibodyDNA DamageResearch PaperInternational journal of medical sciences
researchProduct

Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

2020

Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of peo…

Drugmedicine.medical_specialtyPost exposureCoronavirus disease 2019 (COVID-19)COVID19media_common.quotation_subject030231 tropical medicineHydroxychloroquine ; COVID-19 ; Chloroquine ; SARS-CoV2 ; antiviral ; malaria ; Systemic lupus erythematosus ; Immunomodulation ; CoronavirusLoading doseImmunomodulation03 medical and health sciencesSystemic lupus erythematosus0302 clinical medicineChloroquineInternal medicineMedicine030212 general & internal medicineCoronavirus malaria antiviralmedia_commonlcsh:R5-920business.industryStandard treatmentPublic Health Environmental and Occupational HealthChloroquineHydroxychloroquineClinical trialEditorialInfectious DiseasesSARS-CoV2lcsh:Medicine (General)businessHydroxychloroquinemedicine.drugOne Health
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct

B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)

2020

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival factor which supports autoreactive B cells and prevents their deletion. BAFF expression is closely linked with autoimmunity and is enhanced by genetic alterations and viral infections. Furthermore, BAFF seems to be involved in adipogenesis, atherosclerosis, neuro-inflammatory processes and ischemia reperfusion (I/R) injury. BAFF is commonly overexpressed in Systemic Lupus Erythematosus (SLE) and strongly involved in the pathogenesis of the disease. The relationship between BAFF levels, disease activity and damage accrual in SLE is controversial, but growing evidence is emerging on its role in renal …

ImmunologyAutoimmunitymedicine.disease_causeAutoimmunityPathogenesisImmune systemstomatognathic systemimmune system diseaseshemic and lymphatic diseasesB-Cell Activating FactormedicineHumansLupus Erythematosus SystemicImmunology and Allergyskin and connective tissue diseasesB-cell activating factorB cellB-LymphocytesSystemic lupus erythematosusbusiness.industrymedicine.diseaseBelimumabstomatognathic diseasesmedicine.anatomical_structureVirus DiseasesImmunologyRituximabbusinessmedicine.drugAutoimmunity Reviews
researchProduct

Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome.

2008

Objective To review the current evidence regarding the relationship between systemic lupus erythematosus (SLE) and antiphospholipid syndrome and female infertility, as well as the risks associated with ovarian stimulation for ovulation induction and IVF. To establish, based on this information, guidelines for safe and successful assisted reproductive technology (ART). Design A MEDLINE computer search was performed to identify relevant articles. Result(s) Systemic lupus erythematosus and antiphospholipid syndrome are not related to infertility, except for cases of amenorrhea accompanying severe flares, renal insufficiency-related hypofertility, and ovarian failure secondary to cyclophosphami…

Infertilitymedicine.medical_specialtymedicine.medical_treatmentOvarian hyperstimulation syndromeFertilization in VitroOvulation Inductionimmune system diseasesAntiphospholipid syndromePregnancyRisk FactorsmedicineHumansLupus Erythematosus Systemicskin and connective tissue diseasesIn vitro fertilisationLupus erythematosusSystemic lupus erythematosusbusiness.industryObstetricsFemale infertilityObstetrics and Gynecologymedicine.diseaseAntiphospholipid SyndromeReproductive MedicineImmunologyOvulation inductionFemalebusinessInfertility FemaleFertility and sterility
researchProduct

Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA.

2004

Primary defence against invading microorganisms depends on a functional innate immune system and the complement system plays a major role in such immunity. Deficiencies in one of the components of the complement system can cause severe and recurrent infections, systemic diseases, such as systemic lupus erythematosus (SLE) and renal disease. Screening for complement deficiencies in the classical or alternative complement pathways has mainly been performed by haemolytic assays. Here, we describe a simple ELISA-based format for the evaluation of three pathways of complement activation. The assays are based on specific coatings for each pathway in combination with specific buffer systems. We ha…

Innate immune systemSystemic lupus erythematosusImmunologyComplement Pathway AlternativeComplement Pathway Mannose-Binding LectinEnzyme-Linked Immunosorbent AssayComplement System ProteinsBiologyComplement fixation testmedicine.diseaseMannose-Binding LectinComplement systemComplement (complexity)Immune systemImmunologymedicineImmunology and AllergyHumansLupus Erythematosus SystemicComplement Pathway ClassicalReagent Kits DiagnosticFicolinComplement ActivationMannan-binding lectinJournal of immunological methods
researchProduct

TD-09 IL-34 promotes macrophage-mediated lupus nephritis in MRL-Faslpr mice

2018

Background Nephritis is the major cause of mortality and morbidity in patients with lupus. Macrophages (Mo) are central to kidney destruction in lupus-prone mice and patients. CSF-1, and the newly identified IL-34, mediate Mo survival and proliferation. However, IL-34 and CSF-1 differ during development and disease. While CSF-1 and IL-34 share the CSF-1 receptor (cFMS), expressed by Mo, IL-34 binds to a second receptor, Protein-Tyrosine Phosphatase ζ (PTPRZ) in inflamed kidneys. Intra-renal IL-34, cFMS, and PTPRZ are increased during the progression of lupus nephritis in MRL-Faslpr mice. Therefore, we hypothesized that IL-34 is a potential therapeutic target for lupus nephritis. Methods and…

KidneySystemic lupus erythematosusbusiness.industryLupus nephritisMonocyte proliferationmedicine.diseasePathogenesismedicine.anatomical_structureImmunologymedicineBone marrowbusinessReceptorNephritisTissue Damage
researchProduct